Younossi, Z. et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 69, 2672–2682 (2019).

Article  PubMed  Google Scholar 

Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84 (2016).

Article  PubMed  Google Scholar 

Noureddin, M. et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am. J. Gastroenterol. 113, 1649–1659 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Ascha, M. S. et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51, 1972–1978 (2010).

Article  PubMed  Google Scholar 

Kabbany, M. N. et al. Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the United States: an analysis of national health and nutrition examination survey data. Am. J. Gastroenterol. 112, 581–587 (2017).

Article  PubMed  Google Scholar 

Noureddin, M. & Rinella, M. E. Nonalcoholic fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin. Liver Dis. 19, 361–379 (2015).

Google Scholar 

Donnelly, K. L. et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115, 1343–1351 (2005).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hirsova, P., Ibrabim, S. H., Gores, G. J. & Malhi, H. Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis. J. Lipid Res. 57, 1758–1770 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marra, F. & Svegliati-Baroni, G. Lipotoxicity and the gut–liver axis in NASH pathogenesis. J. Hepatol. 68, 280–295 (2018).

Article  CAS  PubMed  Google Scholar 

Neuschwander-Tetri, B. A. Therapeutic landscape for NAFLD in 2020. Gastroenterology 158, 1984–1998 (2020).

Article  CAS  PubMed  Google Scholar 

Cornell, L. et al. DNA-PK—a candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival. Clin. Cancer Res. 21, 925–933 (2015).

Article  CAS  PubMed  Google Scholar 

Vuppalanchi, R., Noureddin, M., Alkhouri, N. & Sanyal, A. J. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat. Rev. Gastroenterol. Hepatol. 18, 373–392 (2021).

Article  PubMed  Google Scholar 

Sanyal, A. J. et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N. Engl. J. Med. 385, 1559–1569 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anania, F. A., Dimick-Santos, L., Mehta, R., Toerner, J. & Beitz, J. Nonalcoholic steatohepatitis: current thinking from the Division of Hepatology and Nutrition at the Food and Drug Administration. Hepatology 73, 2023–2027 (2021).

Article  PubMed  Google Scholar 

Han, M. A. T. et al. Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 17, 616–629 (2019).

Article  PubMed  Google Scholar 

Ng, C. H. et al. Placebo effect on progression and regression in NASH: evidence from a meta-analysis. Hepatology 75, 1647–1661 (2022).

Article  PubMed  Google Scholar 

Sanyal, A. J. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 16, 377–386 (2019).

Article  PubMed  Google Scholar 

Harrison, S. Mitigating Screen Failures: Finding the Right Patients for Trial Recruitment (EASL, 2022).

Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313–1321 (2005).

Article  PubMed  Google Scholar 

Sanyal, A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675–1685 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cusi, K. et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann. Intern. Med. 165, 305–315 (2016).

Article  PubMed  Google Scholar 

Belfort, R. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355, 2297–2307 (2006).

Article  CAS  PubMed  Google Scholar 

Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328–357 (2018).

Article  PubMed  Google Scholar 

Chalasani, N. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142, 1592–1609 (2012).

Article  PubMed  Google Scholar 

Dulai, P. S. et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65, 1557–1565 (2017).

Article  CAS  PubMed  Google Scholar 

Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389–397 (2015).

Article  PubMed  Google Scholar 

Ekstedt, M. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61, 1547–1554 (2015).

Article  CAS  PubMed  Google Scholar 

Younossi, Z. M. et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 53, 1874–1882 (2011).

Article  PubMed  Google Scholar 

Sanyal, A. J. et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 54, 344–353 (2011).

Article  PubMed  Google Scholar 

Kleiner, D. E. et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw. Open 2, e1912565 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Bedossa, P. et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 56, 1751–1759 (2012).

Article  PubMed  Google Scholar 

Singh, S. & Loke, Y. K. Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials 13, 138 (2012).

Article  PubMed  PubMed Central  Google Scholar 

Björnsson, E. S. Incidence and outcomes of DILI in Western patients. Clin. Liver Dis. 4, 9–11 (2014).

Google Scholar 

Reuben, A., Koch, D. G. & Lee, W. M. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 52, 2065–2076 (2010).

Article  PubMed  Google Scholar 

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (National Institute of Diabetes and Digestive and Kidney Diseases, 2012).

Goldkind, L. & Laine, L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiol. Drug Saf. 15, 213–220 (2006).

Article  CAS  PubMed  Google Scholar 

Grudzinskas, C. Design of clinical development programs. In Principles of Clinical Pharmacology (Second Edition) (eds. Atkinson, A. Jr. et al.) 501–517 (Academic Press, 2007).

Regev, A. et al. Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. Aliment. Pharm. Ther. 49, 702–713 (2019).

Article  Google Scholar 

Guo, T. A tool to help you decide (detect potentially serious liver injury). In Annual Conference of the American Association for the Study of Liver Diseases (AASLD, 2008).

Guo, T. How a SAS/IntrNet tool was created at the FDA for the detection of potential drug-induced liver injury using data with CDISC standard. In Western Users of SAS Software Annual Conference (WUSS, 2009).

Temple, R. Hy’s law: predicting serious hepatotoxicity. Pharmacoepidemiol. Drug Saf. 15, 241–243 (2006).

Article  PubMed  Google Scholar 

Watkins, P. B. et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 34, 243–252 (2011).

Article  PubMed  Google Scholar 

Davison, B. A. et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J. Hepatol. 73, 1322–1332 (2020).

Article  CAS  PubMed  Google Scholar 

Sumida, Y., Nakajima, A. & Itoh, Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J. Gastroenterol. 20, 475–485 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Tian, G., Kong, D., Jiang, T. & Li, L. Complications after percutaneous ultrasound-guided liver biopsy: a systematic review and meta-analysis of a population of more than 12,000 patients from 51 cohort studies. J. Ultrasound Med. 39, 1355–1365 (2020).

Article